How much revenue does Divi's Laboratories make?

Divi's Laboratories reported 93.25 billion INR in revenue for fiscal year 2025, up 19.6% from 77.96 billion INR in fiscal year 2024. In Q1 2026 revenue was 24.10 billion INR.

Where does Divi's Laboratories make most of its revenue?

Other Countries: 54% of revenue by region in fiscal year 2025, followed by Switzerland (20%).

What companies are similar to Divi's Laboratories?

Listed companies of a similar size in the same industry (drug manufacturing contractors) include Laurus Labs Limited (LAURUSLABS.NS), Gland Pharma Limited (GLAND.NS), Neuland Laboratories Limited (NEULANDLAB.NS), Piramal Pharma Limited (PPLPHARMA.NS).

Divi's Laboratories Limited (DIVISLAB.NS) Stock

About Divi's Laboratories Limited

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, ca...

At a glance

Divi's Laboratories reported revenue of 93.25 billion INR for fiscal year 2025, up 19.6% from fiscal year 2024, and net income of 21.91 billion INR. In Q1 2026 (the quarter ended June 30, 2025) revenue was 24.10 billion INR, up 13.8% from a year before. Other Countries was its largest region in fiscal year 2025, with 54% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.